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   STABILITY INDICATING LIQUID 
CHROMATOGRAPHIC METHOD FOR THE 
ESTIMATION OF DESVENLAFAXINE IN 
PHARMACEUTICAL DOSAGE FORM 
A simple, sensitive, precise and stability indicating liquid chromatographic 
method has been developed for the estimation of desvenlafaxine succinate in 
pharmaceutical dosage form. A Hypersil C-18, 5 μm-column with a mobile 
phase containing 0.05 M potassium dihydrogen phosphate:methanol (60:40 
v/v), pH 7, was used. The flow rate was 1.0 mL/min and effluents were moni-
tored at 226 nm. The retention time of desvenlafaxine was 7.4 min and the 
method was linear in the range of 0.1-20 µg/mL. Desvenlafaxine stock solution 
was subjected to acid and alkali hydrolysis, chemical oxidation and dry heat 
degradation. The drug was found to be susceptible to base hydrolysis and 
developed method was found to give good separation between the pure drug 
and the degraded product. The method was successfully applied to the es-
timation of desvenlafaxine in tablet dosage forms. 
Key words: desvenlaflaxine; degradation; reversed phase liquid chromato-
graphy; validation. 
 
 
Desvenlafaxine succinate (DVX) is chemically 
RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]-
phenol succinate monohydrate. It is a salt form of the 
major active metabolite of venlafaxine. Desvenla-
faxine inhibits serotonergic and noradrenergic reup-
take receptors with minimal affinity for muscarinic, 
cholinergic, histaminergic, and α1-adrenergic recep-
tors [1]. Desvenlafaxine lacks monoamine oxidase 
inhibitory activity. Serotonergic receptors are inhibited 
approximately 10-fold more than noradrenergic recep-
tors. Based on the in vitro results and the relationship 
between desvenlafaxine and venlafaxine, desvenla-
faxine is classified as a selective serotonin and nore-
pinephrine reuptake inhibitor (SNRI). Approximately 
75% of venlafaxine is metabolized into O-desmethyl-
venlafaxine or desvenlafaxine
 by the action of CYP2D6 
on parent drug [2]. Desvenlafaxine is not predomi-
nately metabolized by the cytochrome P450 (CYP) 
system and is eliminated primarily by phase II meta-
bolism; as a result, it has lower potential for drug 
interactions, especially with the CYP 2D6 pathway.
 It 
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has been approved for the treatment of major depres-
sive disorder (MDD) and has also been studied for the 
treatment of vasomotor symptoms associated with 
menopause [3-4]. Preliminary evidence also suggests 
the clinical usefulness of DVX in the treatment of an-
xiety symptoms, and painful physical symptoms [5-6]. 
A literature survey regarding quantitative ana-
lysis of the drug revealed that attempts have been 
made to develop analytical methods for the estimation 
of DVX in human plasma using HPLC with fluores-
cence detection [7-9], HPLC with UV detection [10], 
LC-MS/MS [11-13] and HPLC-ESI/MS [14].  
The International Conference on Harmonization 
(ICH) guidelines [15] require the implementation of 
stress testing procedures for the identiﬁcation of de-
gradation products that are potentially occurring in 
drug substances which can help to understand the 
possible degradation pathway for the drug. The ap-
parent lack of a method for the estimation of desven-
lafaxine in pharmaceutical dosage form prompted us 
to develop an accurate, specific and sensitive liquid 
chromatographic method. 
EXPERIMENTAL 
Apparatus 
The liquid chromatographic system consisted of 
a Perkin Elmer HPLC model (200 series) containing D.A. SHAH et al.: STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD…  CI&CEQ 17 (3) 341−348 (2011) 
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series 200 quaternary gradient pump, variable wave-
length programmable UV/Vis detector and Rheodyne 
injector with 20 μL fixed loop. Chromatographic ana-
lysis was performed on a Hypersil C-18 column 
having 250 mm×4.6 mm i.d. and 5 μm particle size. 
All the drugs and chemicals were weighed on Shi-
madzu electronic balance (AX 200, Shimadzu Corp., 
Japan). 
Chemicals and reagents 
Analytically pure DVX was obtained as gift 
samples from Precise Chemipharma Ltd., India. HPLC 
grade methanol and water were obtained from E. 
Merck Ltd., Mumbai, India, while analytical reagent 
grade potassium dihydrogen phosphate, sodium hyd-
roxide, hydrochloric acid, hydrogen peroxide and tri-
ethylamine were obtained from S. D. Fine chemicals, 
Mumbai, India. Tablet formulation Zyven-OD (Zydus 
Healthcare Ltd., India) containing 50 mg of desven-
lafaxine was procured from a local market. 
Chromatographic conditions 
A reverse phase C-18 column (250 mm×4.6 mm 
i.d.) equilibrated with mobile phase 0.05 M potassium 
dihydrogen phosphate:methanol (60:40, v/v), pH 7, 
(adjusted using triethylamine) was used. Mobile phase 
flow rate was maintained at 1 mL/min and effluents 
were monitored at 226 nm. Chromatographic system 
was operated at controlled room temperature 25±2 °C. 
Preparation of standard stock solution 
Stock solution was prepared by accurately weigh-
ing 25 mg of DVX and transferring to a 25 mL volu-
metric flask containing a few mL of methanol. The 
flask was swirled to dissolve the solids. Volume was 
made up to the mark with methanol to yield a solution 
containing 1000 μg/mL of DVX. Aliquot from the stock 
solution of DVX was appropriately diluted with mobile 
phase to obtain working standard solution of 100 μg/mL. 
Calibration curve for DVX 
Appropriate aliquots of DVX working standard 
solution were taken in different 10 mL volumetric 
flasks. The volumes were made up to the mark with 
mobile phase to obtain final concentrations of 0.1, 
0.5, 1, 5, 10 and 20 µg/mL of DVX. The solutions 
were injected and chromatograms were recorded. 
The calibration curve (n = 5) was constructed by plot-
ting peak area versus concentration of the drug and 
regression equations were computed. 
Validation 
The method was validated for accuracy, preci-
sion, specificity, detection limit, quantitation limit and 
robustness as per ICH guideline [15]. 
Accuracy. The accuracy of the method was de-
termined by calculating recoveries of DVX by method 
of standard additions. Known amounts of DVX (0, 4, 
7.5 and 12 μg/mL) were added to a pre-quantified 
sample (7.5 μg/mL) and the amounts of DVX were 
estimated by measuring the peak area and by fitting 
these values to the straight-line equation of calibration 
curve. 
Precision. The instrumental precision was eva-
luated by injecting the solution containing DVX (10 
μg/mL) six times repeatedly and measuring the peak 
area. The results are reported in terms of relative 
standard deviation. The intra-day and inter-day pre-
cision study of DVX was carried out by estimating the 
corresponding responses 3 times on the same day 
and on 3 different days (first, second and third day) 
for 3 different concentrations of DVX (0.1, 5 and 20 
μg/mL) and the results are reported in terms of re-
lative standard deviation (RSD). 
Specificity. The specificity was estimated by spi-
king commonly used excipients (starch, talc and mag-
nesium stearate) into a pre-weighed quantity of drug. 
The chromatogram was taken by appropriate dilutions 
and the quantities of drugs were determined.  
Limit of detection and quantification. The detec-
tion limit is defined as the lowest concentration of an 
analyte that can reliably be differentiated from back-
ground levels. Limit of quantification of an individual 
analytical procedure is the lowest amount of analyte 
that can be quantitatively determined with suitable 
precision and accuracy. LOD and LOQ were calcu-
lated using following equation as per ICH guidelines. 
LOD = 3.3σ/S and LOQ = 10σ/S, where σ is the 
standard deviation of y-intercepts of regression lines 
and S is the slope of the calibration curve.  
Robustness. Robustness of the method was stu-
died by deliberately changing the experimental condi-
tions like flow rate, percentage of organic phase and 
also by observing the stability of the sample solution 
at 25±2 °C after 24 h. 
Forced degradation study 
Stress degradation study using acid and alkali 
hydrolysis, chemical oxidation and dry heat degrada-
tion was carried out and interference of the degra-
dation products was investigated. DVX was weighed 
(25 mg each) and transferred to a 25 mL volumetric 
flask and diluted up to the mark with mobile phase. 
This stock solution was used for forced degradation 
studies. 
a) Base hydrolysis. Forced degradation in basic 
media was performed by taking 2.5 mL stock solution 
of DVX in 25 mL volumetric flasks and 5 mL of 1 M D.A. SHAH et al.: STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD…  CI&CEQ 17 (3) 341−348 (2011) 
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NaOH was added. The solution was heated in a water 
bath at 70 °C for 1 h and allowed to cool to room tem-
perature. Solution was neutralized with 1 M HCl using 
pH meter and suitably diluted with mobile phase to 
obtain final concentration of 10 μg/mL of DVX. 
b) Acid hydrolysis. Forced degradation in acidic 
media was performed by taking 2.5 ml of stock so-
lution of DVX in 25 mL volumetric flasks and 5 ml of 
1 M HCl was added. The flask was heated in a water 
bath at 70 °C for 1 h and allowed to cool to room 
temperature. Solution was neutralized with 1 M NaOH 
using pH meter and suitably diluted with mobile phase 
to obtain final concentration of 10 μg/mL of DVX. 
c) Oxidative stress degradation. To perform oxi-
dative stress degradation, 2.5 mL stock solution of 
DVX was taken in a 25 mL volumetric flask and 5 mL 
of 3% hydrogen peroxide was added. The flask was 
heated in a water bath at 70 °C for 1 h and allowed to 
cool to room temperature. Solution was appropriately 
diluted with mobile phase to obtain final concentration 
of 10 μg/mL of DVX. 
d) Dry heat degradation. To study dry heat de-
gradation, solid drug was exposed in oven at 80 °C 
for 2 h. The solid was allowed to cool and 25 mg of 
DVX was weighed, transferred to volumetric flask (25 
mL) and dissolved in few mL of methanol. Volume 
was made up to the mark with the methanol. Appro-
priate aliquot was taken from above solution and di-
luted with mobile phase to obtain final concentration 
of 10 μg/mL of DVX. 
All the reaction solutions were injected in the 
liquid chromatographic system and chromatograms 
were recorded. 
Analysis of marketed formulations 
Twenty tablets were weighed accurately and 
finely powdered. Tablet powder equivalent to 50 mg 
of DVX was accurately weighed and transferred to a 
50 mL volumetric flask. A few mL (20 mL) of mobile 
phase was added to the above flask and sonicated for 
5 min. The solution was filtered using Whatman filter 
paper No. 1 in another 50 mL volumetric flask and vo-
lume was diluted to the mark with the mobile phase. 
Appropriate volume of the aliquot was transfer-
red to a 25mL volumetric flask and the volume was 
made up to the mark with mobile phase to obtain 7.5 
μg/mL of DVX. The solution was injected at above 
chromatographic conditions and peak areas were 
measured. The quantification was carried out by keep-
ing these values to the straight line equation of cali-
bration curve. 
RESULTS AND DISCUSSION 
Optimization of mobile phase 
Optimization of mobile phase was performed to 
obtain a well resolved peak for active drug ingredient 
(DVX) and degradation products produced under stres-
sed conditions. Various mixtures containing aqueous 
buffer-methanol were tried as mobile phases. 
Different mobile phases tried were metha-
nol:0.025 M potassium dihydrogen phosphate (80:20 
v/v) which gave peak for DVX at 2.95 min with unsa-
tisfactory peak resolution, methanol:0.025 M potas-
sium dihydrogen phosphate (80:20 v/v), pH 6.8, which 
gave peak for DVX at 3.45 min and methanol: 0.05 M 
potassium dihydrogen phosphate (60:40 v/v), pH 8, 
which gave peak for DVX at 3.93 min. 
The mobile phase consisting of 0.05 M potas-
sium dihydrogen phosphate:methanol (60:40, v/v), pH 
7, was selected which gave sharp peak for DVX 
(Figure 1). The flow rate was maintained at 1.0 mL/min. 
The retention times for DVX was 7.4 min. Ultraviolet 
spectra of DVX showed that the drug absorbed appre-
ciably at 226 nm, so the same was selected as the 
detection wavelength during chromatographic studies. 
Validation 
The developed method was validated as per 
ICH guideline. The calibration curve (n = 5) was found 
to be linear over the range of 0.1-20 μg/mL for DVX. 
The data of regression analysis of the calibration cur-
ves are shown in Table 1. The accuracy of the me-
thod was determined by calculating recoveries of DVX 
by method of standard additions. The recoveries were 
found to be 95.81-102.2%. The high values indicate 
that the method is accurate. Instrument precision was 
determined by performing injection repeatability test 
and the RSD value for DVX were found to be 1.2%. 
The intra-day and inter-day precision studies were 
carried out. For the intra-day study RSD values were 
found to be 0.8-1.3% for DVX and for inter-day pre-
cision study RSD values were found to be 1.2-1.6% 
for DVX. The low RSD values indicate that the me-
thod is precise. The detection limit for DVX was 0.03 
μg/mL, while quantitation limit was 0.1 μg/mL, respec-
tively. The above data shows that a nanogram quan-
tity of drug can be accurately and precisely deter-
mined. The validation parameters are summarized in 
Table 2. 
Robustness of the method was studied by chan-
ging the flow rate of the mobile phase from 1mL/min 
to 0.8 and 1.2 mL/min. Using 1.2 mL/min flow rate, re-
tention time for DVX was observed to be 6.05 min and 
with 0.8 mL/min flow rate retention times for DVX was D.A. SHAH et al.: STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD…  CI&CEQ 17 (3) 341−348 (2011) 
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observed to be 9.08 min. When mobile phase compo-
sition was changed to 0.05 M potassium dihydrogen 
phosphate:methanol (55:45 v/v) by increasing percen-
tage of methanol, the retention time for DVX was 
observed to be 5.72 min. The solution stability study 
revealed that DVX solution was stable for 24 h with-
out detectable degradation and the percentage reco-
very of was found to be more than 98%. 
Table 1. Regression analysis of calibration curve 
Parameters  DVX 
Linearity range, μg/mL 0.1-20 
Slope 29470.83 
Standard deviation of slope  367.5657 
Intercept 6313.833 
Standard deviation of intercept  303.463 
Correlation coefficient  0.998 
Forced degradation study 
The chromatograms of base degraded sample 
showed degradation product peaks at retention time 
(RT) 2.45, 3.51, 4.01 and 6.13 min (Figure 2). The 
degradation product peaks were well resolved from 
drug peak (R > 2). The chromatogram of acid deg-
raded samples showed no degradation products peaks. 
DVX was found to be stable to acid hydrolysis at room 
temperature and at 70 °C (Figure 3). Oxidative stress 
degradation sample showed degradation peak at re-
tention time 4.12 and 4.50 min. Peaks around 0.2-1.5 
min in the chromatogram is because of the impurities 
present in the hydrogen peroxide (Figure 4). Dry heat 
degradation study revealed that there is no deg-
radation peak for DVX (Figure 5). The drug was found 
to be stable. 
Table 2. Summary of validation and system suitability parame-
ters 
Parameters DVX 
Retention time, min  7.4 
Asymmetry 1.3 
Theoretical plates  11469 
Detection limit, μg/mL 0.03 
Quantitation limit, μg/mL 0.1 
Accuracy, %  95.81–102.2 
Precision (RSD / %) 
Intra-day (n = 3)  0.8–1.3 
Inter-day (n = 3)  1.2-1.6 
Instrument precision  1.2 
The forced degradation study thereby indicated 
that DVX was found to be susceptible to base hyd-
rolysis and oxidative stress degradation while it was 
stable to acid hydrolysis and dry heat degradation 
study (Table 3). The degradation product peaks were 
well resolved from drug peak with a resolution of 
more than 2. 
 
Figure 1. Liquid chromatogram of desvenlafaxine succinate in mobile phase. D.A. SHAH et al.: STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD…  CI&CEQ 17 (3) 341−348 (2011) 
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Figure 2. Chromatogram of base treated DVX (10 μg/mL) at 70 °C for 1 h. 
 
Figure 3. Chromatogram of acid treated DVX (10 μg/mL) at 70 °C for 1 h. 
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Figure 4. Chromatogram of hydrogen peroxide (3%) treated DVX (10 μg/mL) at 70 °C for 1 h. 
 
Figure 5. Chromatogram of DVX (10 μg/mL) after dry heat exposure at 80 °C for 2 h. 
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Table 3. Forced degradation study of DVX for the proposed LC method 
Medium  Conditions  Recovery, % (DVX)  Retention times of degradation products, min 
Base, 1 M NaOH  70 °C for 1 h  54.94  2.45, 3.51, 4.01 and 6.13 
Acid, 1 M HCl  70 °C for 1 h  98.45  - 
3% Hydrogen peroxide  70 °C for 1 h  86.58  4.12 and 4.50 
Dry heat  80 °C for 2 h  97.25  - 
 
Analysis of marketed formulations 
The proposed method was applied to the deter-
mination of DVX in tablet dosage form. The assay 
results obtained were 98.88±0.45 (n = 3) which was 
comparable with the corresponding labeled amount. 
CONCLUSION 
The proposed study describes a stability indi-
cating liquid chromatographic method for the esti-
mation of DVX in pharmaceutical dosage form. The 
method was validated and found to be simple, sensi-
tive, accurate and precise. The method was success-
fully used for determination of drug in its pharmaceu-
tical formulation. Also, the above results indicate the 
suitability of the method for acid, base, dry heat and 
oxidative degradation study of drug. As the method 
separates the drugs from its degradation products, it 
can be used for analysis of stability samples of drug. 
In future, isolation and characterization of degradation 
product can be carried out and pharmacological effect 
of isolated degradation product can be evaluated.  
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NAUČNI RAD 
   ODREĐIVANJE SADRŽAJA I STABILNOSTI 
DESVENLAFAKSINA U FARMACEUTSKIM 
PREPARATIMA METODOM TEČNE 
HROMATOGRAFIJE 
Razvijena je jednostavna, osetljiva i precizna metoda tečne hromatografije za određiva-
nje sadržaja i stabilnosti desvenlafaksin-sukcinata u farmaceutskim preparatima. U radu 
je korišćena kolona Hypersil C-18, prečnika 5 μm, sa mobilnom fazom 0,05 M kalijum-di-
hidrogen-fosfat:metanol (60:40 v/v), pH 7. Protok je bio 1,0 ml/min, a efluenti su praćeni 
na 226 nm. Retenciono vreme desvenlafaksina je 7,4 min, a linearnost važi u opsegu 
koncentracije 0,1-20 µg/ml. Osnovni rastvor desvenlafaksina je podvrgnut kiselinskoj i 
baznoj hidrolizi, hemijskoj oksidaciji i suvoj termičkoj degradaciji. Utvrđeno je da je lek 
osetljiv na baznu hidrolizu i da razvijena metoda dobro razdvaja čist lek od degrada-
cionih proizvoda. Ova metoda je uspešno primenjena za određivanje desvenlafaksina u 
tabletama. 
Ključne reči: Desvenlafaksin, degradacija, tečna hromatografija na obrnutim fa-
zama, validacija. 
 
 